WAR 0 9 2016 Weller the

1644 JOU AF

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ection of information unless it displays a valid OMB control number. the Paperwork Reduction Act of 1995, no persons are required to respond to a coll Application Number 08/323.060 Filing Date TRANSMITTAL October 14, 1994 First Named Inventor **FORM** Philip C. Comp Art Unit 1644 **Examiner Name** Ronald B. Schwadron (to be used for all correspondence after initial filing) Attorney Docket Number OMRF:038USC1 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Amendment Following Decision on Appeal Request for Refund **Express Abandonment Request** and Postcard. CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Reply to Missing Parts/ Jaworski L.L.P. Account No.: 50-1212/OMRF:038USC1. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Fulbright & Jav Signature Printed name Steven L. Highlander Date Reg. No. 37,642 February 28, 2005 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Steven L Highlander

Typed or printed name

Date

February 28, 2005





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: PHILIP C. COMP

Serial No.: 08/323,060

Filed: October 14, 1994

For: BLOCKADE OF PROTEIN C

ACTIVATION REDUCES

MICROVASCULAR SURGICAL BLOOD

LOSS

Group Art Unit: 1644

Examiner: Ronald B. Schwadron

Atty. Dkt. No.: OMRF:038USC1

AMENDMENT FOLLOWING DECISION ON APPEAL

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This is in response to the decision on appeal regarding the above-captioned application. Applicants seek to cancel the appealed and rejected claims, allowing previously allowed claims to issue. No fees are believed due in connection with this filing. However, should any fees be due, the Commissioner is authorized to debit Fulbright & Jaworski Deposit Account No. 55-1212/OMRF:038USC1/SLH. Please date stamp and return the enclosed postcard as evidence of receipt.

Amendments to the Claims begin on page 2 of this paper; Remarks begin on page 3.